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Abstract Conventional MR imaging (MRI) techniques
form the cornerstone of multiple sclerosis (MS) diagnostics
and clinical follow-up today. MRI is sensitive in demon-
strating focal inflammatory lesions and diffuse atrophy.
However, especially in progressive MS, there is increas-
ingly widespread diffuse pathology also outside the pla-
ques, often related to microglial activation and
neurodegeneration. This cannot be detected using conven-
tional MRI. Positron emission tomography (PET) imaging
using 18-kDa translocator protein (TSPO) binding radioli-
gands has recently shown promise as a tool to detect this
diffuse pathology in vivo, and for the first time allows one to
follow its development longitudinally. It is becoming evi-
dent that the more advanced the MS disease is, the more
pronounced is microglial activation. PET imaging allows
the detection of MS-related pathology at molecular level
in vivo. It has potential to enable measurement of effects of
new disease-modifying drugs aimed at reducing neurode-
generation and neuroinflammation. PET imaging could thus
be included in the design of future clinical trials of pro-
gressive MS. There are still technical issues related to the
quality of TSPO radioligands and post-processing
methodology, and comparison of studies from different
PET centres is challenging. In this review, we summarise
the main evidence supporting the use of TSPO-PET as a
tool to explore the diffuse inflammation in MS.
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Introduction
Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system (CNS), where neuroinflammation
and neurodegeneration are the two main components in the
pathogenesis. Even though the fundamental cause of the
disease is not entirely understood, several environmental
and genetic predisposing factors have been identified. The
clinical presentation of MS is heterogeneous, with the most
typical form at the onset of the disease being relapsing–
remitting MS (RRMS) which is characterised by acute
worsenings of neurological symptoms followed by a full or
partial recovery. RRMS shifts into secondary progressive
MS (SPMS) on average 10 years after disease onset, and
slowly cumulating symptoms lead to irreversible and pro-
gressive disability [1].
The inflammatory activity in RRMS can be suppressed
with disease-modifying therapies; these can reduce the
number of relapses, and the progression of the disease can
be slowed down to some extent [2]. Tragically, there is no
curative treatment for MS and moreover, no effective
treatment is available to prevent the cumulative disability
in the progressive forms of the disease. Being the most
common disability causing neurological disease in young
adults [3], the socioeconomic impact of MS is considerable
both in terms of individual suffering and its burden on the
health service budget [1, 4]. Thus, more research is clearly
needed to understand the pathophysiology, to develop
alternative biomarkers for the evaluation of disease activ-
ity, and to seek alternative pathways for therapeutic
development in the treatment of progressive MS.
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According to current understanding, both neuroinflam-
mation and neurodegeneration occur during all stages of
MS [3, 5–7]. Axonal loss underlies especially the transition
from relapsing to progressive MS, but neurodegeneration
with axonal transections is known to be present already
early in the disease [1, 8]. By studying progressive MS, one
may thus gain important insights about the degenerative
component of MS present in all stages of the disease.
MR imaging (MRI) remains the cornerstone of modern
clinical diagnostics and follow-up of inflammatory activity
and gross atrophy related to MS. However, MRI does not
allow examination of the specific molecular pathophysiol-
ogy and neuroreceptor binding related to MS pathology.
Positron emission tomography (PET) imaging on the other
hand enables molecular and neuroreceptor imaging in vivo.
Particularly relevant for the study of MS is PET imaging of
activated microglia. Here, several radioligands binding to
the 18 kDa translocator protein (TSPO)—a protein struc-
ture expressed on the outer mitochondrial membrane of
activated, but not resting microglia—have been developed
[9].
Microglia in MS
Microglia are myeloid cells of the central nervous system
(CNS), that are derived from early embryonic ery-
thromyeloid progenitor cells and have migrated into the
developing nervous tissue, where they have begun the
maturation process into brain-resident microglial cells [10].
Microglia constitute approximately 10 percent of the total
cell population in a human brain. The key tasks performed
by microglia include phagocytosis of extracellular debris,
antigen presentation to host immune cells, and secretion of
inflammatory mediators [11].
In the early phase of MS, microglial activation promotes
the recruitment of naı¨ve T cells, which are activated in the
periphery by dendritic cells functioning as antigen-pre-
senting cells. Microglia also act as antigen-presenting cells,
re-stimulating the auto-reactive memory-T-cells invading
through the blood–brain barrier (BBB) into the CNS. This
is considered a key event in maintaining the chronic
inflammation in the CNS [12, 13]. In active white matter
lesions, there is a profound infiltration of activated
microglia and blood-borne macrophages throughout the
lesion, whereas in slowly expanding (smouldering) or
chronic active lesions, the microglia and macrophages are
concentrated as a dense rim around the lesions [6, 14].
Microglia have also been found diffusely in white and gray
matter with concomitant axonal degeneration and menin-
geal inflammation. Thus, chronic activation of microglia
has been linked to neurodegeneration in the progressive
phase of the disease [15–17]. In progressive MS disease,
activation of microglia has been detected in areas of the
brain which appear normal in conventional MRI, the so-
called normal appearing white matter (NAWM) [5, 6].
When microglia are activated following an insult, they
become mobile and capable of phagocytosis and antigen
presentation. The phagocytosis of debris by microglia is
thought to be essential for enabling the return of normal
tissue homeostasis after an insult. In chronic neuroinflam-
mation, the equilibrium between debris-clearing and
inflammation-propagating microglia becomes unbalanced,
and the overactivated microglia cause uncontrolled neu-
ronal damage resulting in a self-propagating vicious cycle
and progressive neurodegeneration [18]. It is thus possible
that prolonged inflammation related to activated microglial
cells is one of the driving forces of the chronic progression
of MS disease. Presently, the differentiation between acti-
vated brain-resident microglia and blood-derived macro-
phages—which may possess different functions—is
challenging, and might distort the interpretation of in vitro
and in vivo studies on the role of microglia in health and
disease. Notwithstanding the lack of understanding the
exact role of the myeloid cells in the different stages of MS
pathogenesis, the presence of activated microglia is well
established in the MS brain.
TSPO and activated microglia
Activated microglia express the TSPO, earlier called the
peripheral benzodiazepine receptor (PBR) on the outer
membrane of mitochondria. Several functions have been
attributed to TSPO, either directly or indirectly, including
immunomodulation, regulation of cholesterol transport,
synthesis of steroid hormones, apoptosis, cell proliferation,
porphyrin and anion transport, regulation of mitochondrial
functions and heme synthesis [19]. Structurally, TSPO is an
18 kDa macromolecular protein with a structure of five
alpha helices spanning the membrane lipid bilayer. Two
archetypal ligands binding to TSPO have been identified,
namely Ro5-4864, the 4-chloro-derivative of diazepam,
and PK11195, the isoquinoline carboxamide [20], the latter
having been used as a marker for in vivo PET imaging of
activated microglia.
Whereas TSPO is highly expressed in activated micro-
glia, in the ‘‘resting’’ or surveying microglia, it is expressed
at a lower level, and mainly in the gray matter [21]. As a
marker of microglial activation, TSPO expression has been
shown to be increased in many cerebral pathological states,
such as Huntington’s disease (HD) [22], brain ischemia
[23] and MS [24]. In Parkinson’s disease (PD) and Alz-
heimer’s disease (AD), some neuropathological studies
have found evidence of increased microglial activation
[25], in line with the in vivo findings of increased TSPO
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binding in some studies of PD [26, 27] and AD [28, 29]. In
addition, TSPOs are highly expressed in gliomas [30, 31],
with the majority of the expression being accounted for by
tumour cells instead of microglia [32]. More in-depth
reviews on the role of TSPO in disease pathologies of AD,
PD and glioma are also presented in this special issue. In
non-neoplastic CNS damage without BBB breakdown,
microglia are the main cell population expressing TSPO
[33]. In focal damage with BBB breakdown, also TSPO
expressing activated macrophages—cells which have
invaded from the peripheral blood into brain par-
enchyma—are present [34]. Taken together, TSPO upreg-
ulation on microglial cells is considered to be a sensitive
‘‘real-time’’ marker of neuroinflammation and neuronal
injury, reflecting mainly microglial activity, and to some
extent reactive astrocytes [35, 36].
TSPO-PET ligands in MS studies
TSPO has been the most widely used target in the PET
imaging of neuroinflammation. For more than 25 years, the
prototypic TSPO radioligand in use has been
[11C]PK11195, with the first human brain studies con-
ducted in patients with glioma [37], Rasmussen’s
encephalitis [38], and in healthy controls and MS patients
[24]. The use of [11C]PK11195 in clinical studies has been
somewhat impeded due to its relatively low signal-to-noise
ratio [39] despite of its high specificity for TSPO [40]. The
low signal-to-noise ratio leads to uncertainty about the
proportion of specific (displaceable) binding, which com-
plicates accurate modelling of the signal. This character-
istic has been attributed to the ligand’s rather low
penetration through the BBB [9], as well as to the ligand’s
binding to structures in the brain vasculature, where
endothelial and smooth muscle cells also express TSPO
[35]. Reactive astrocytes are also known to overexpress
TSPO in response to injury [41] probably adding to the
non-microglial specific binding [42, 43]. In addition,
instead of [11C](R)PK11195, the earliest studies [24, 37]
used the racemic mixture of [11C]PK11195—which is also
a confounding factor when comparing the older and newer
studies. Another challenge related to MS studies and the
TSPO ligands is the lack of anatomically clearly defined
reference region devoid of specific binding. This is par-
ticularly relevant in neuroinflammatory and neurodegen-
erative diseases with diffusely dispersed pathologies—such
as in MS. Quantitative analytical techniques, either using
the input function from arterial sampling or reference
regions extracted by supervised clustering algorithms, have
been developed for signal quantification. To overcome the
lack of a suitable reference region, an automated method
for the supervised clustering of normal gray matter refer-
ence for [11C](R)-PK11195 PET images has been devel-
oped (SuperPK software; Imperial College, London, UK)
[44–46]. Briefly, in this methodology, a set of predefined
kinetic tissue class time-activity curves (TACs), repre-
senting the average kinetics of the radiotracer in different
types of brain tissue is first created. Thereafter, a weighted
linear combination of tissue class TACs is fitted to each
voxel-wise TAC of the dynamic PET image, which is
standardised using frame-wise means and standard devia-
tions [46]. Consequently, a weight coefficient for each PET
image voxel, that represents the contribution of each
kinetic class to the corresponding TAC, is provided. This
methodology has already been successfully applied in
patients with Alzheimer’s disease [44, 46] and MS [47–49].
Numerous second-generation TSPO radioligands with
higher affinity and specificity than their predecessor
[11C](R)-PK11195 have been developed [9, 50]. However,
the utility of second-generation TSPO ligands in clinical
studies in humans has so far been hampered by these
ligands’ mixed affinity binding phenotype, which has
recently been discovered to be attributed to TSPO gene
polymorphism in humans [51], a phenomenon, however,
not affecting [11C](R)-PK11195 binding. A single nucleo-
tide polymorphism (22q13.2 rs6971) in the TSPO gene
leads to a replacement of cytosine (C) with thymidine
(T) leading to alanine being replaced with threonine in
position 147 in the protein. This in turn leads to three
different phenotypes with regard to the TSPO binding
affinity: low affinity binders (LAB; T/T; threonine/thre-
onine homozygote), mixed affinity binders, (MAB; C/T,
alanine/threonine heterozygote) and high affinity binders
(HAB; C/C, alanine/alanine homozygote), of which HAB
is the most common phenotype (49 %) in a Caucasian
population, followed by MAB (42 %) and LAB (9 %) [51].
In LAB subjects, the binding of the second-generation
TSPO ligands in the brain is too low to permit a reliable
quantification of activated microglia with PET [52, 53].
However, if the binding class is known a priori, then the
LAB subjects can be excluded, and subsequently the results
stratified according to MAB and HAB groups; then, the
within-subject variability of the second-generation ligands
is significantly lower than can be achieved with [11C](R)-
PK11195. Consequently, the sample sizes needed to reveal
50 % differences in between-group analyses would be
approximately half of those needed with [11C](R)-
PK11195 [54]. To acquire the binding class information,
one must perform peripheral blood sampling to allow
genetic testing of the TSPO polymorphism. In addition,
despite their better signal-to-noise ratio than [11C](R)-
PK11195, the second-generation TSPO ligands have also
been shown to bind to reactive astrocytes [55, 56].
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TSPO-PET studies of relapsing MS patients
[11C](R)-PK11195
PET imaging of activated microglia with TSPO-binding
radioligands is being increasingly utilised in MS research.
The first in vivo TSPO-PET pilot study in MS patients with
[11C] (R)-PK11195 revealed that TSPO binding was
increased in acute lesions but was low in chronic lesions
[24]. Thereafter, another study detected a pattern of
increased TSPO binding in scattered areas related to
demyelinating lesions in MRI (excluding black holes) and
also in NAWM and central gray matter (thalami and
brainstem); the majority of the subjects in the study were
RRMS patients [34]. Subsequently, Debruyne and col-
leagues [57, 58] reported that TSPO binding was elevated
in gadolinium-enhancing active plaques, and in non-en-
hancing T2 lesions during relapse, when compared to T2
lesions in patients without relapse. However, the T2
lesional binding was at a similar or lower level than in
NAWM. Interestingly, the TSPO binding in the NAWM
showed an increasing trend associating to longer disease
duration. The patient characteristics in these early studies
were heterogeneous, with patients representing both RRMS
and SPMS as well as primary progressive (PPMS) clinical
subtypes of the disease. Further analyses by the same group
showed that increasing brain atrophy was associated with
higher TSPO binding in NAWM but lower binding in T2
lesional brain [59].
The effect of disease-modifying treatment on microglial
activation has been evaluated in only one MS study. In this
study, 1-year treatment of RRMS with glatiramer acetate
reduced TSPO binding significantly in both cortical GM
and cerebral WM when compared to cerebellum [59].
Politis and colleagues demonstrated increased [11C](R)-
PK11195 binding in the cerebral cortex and in the white
matter in both SPMS and RRMS patients when compared
to healthy controls. Moreover, the cortical TSPO binding
correlated with the clinical disability, the correlation being
more evident in patients with SPMS than in those with
RRMS. Similar correlation was not found for WM [47]. In
another study, the total TSPO binding in the NAWM pre-
dicted the conversion of clinically isolated syndrome (CIS)
to RRMS [61]. Tables 1 and 2 list all MS studies per-
formed so far using the radioligand [11C](R)-PK11195.
Second-generation TSPO radioligands
Until today, only few studies with second-generation TSPO
ligands have been performed in MS patients in vivo. The
inability of [11C]PBR28 and [18]FEDAA1106 to reveal
differences in the TSPO binding in WM or GM between
healthy controls and MS patients in the studies by Oh and
colleagues [62] and Takano et al. [63], respectively, is most
likely explained by the high variation in the specific
binding caused by the TSPO gene polymorphism, since the
role of this genetic variation in TSPO binding was not
established until recently [51]. The study by Oh et al. found
that the ratio of WM to GM uptake of [11C]PBR28 was
increased in RRMS in comparison to healthy controls.
Similarly, [11C]PBR28 binding was also increased in
gadolinium-enhancing active plaques [62]. Interestingly, in
some lesions, a focal increase in [11C]PBR28 binding
preceded the appearance of gadolinium enhancement,
pointing to a role for early glial activation in MS lesion
development [62]. Another pilot study with 4 RRMS
patients detected similar patterns of TSPO binding with the
second-generation TSPO ligand [11C]vinpocetine when
compared to [11C](R)-PK11195, but with higher binding
potentials and a better signal-to-noise ratio [64]. Impor-
tantly, a recent test–retest study with [11C]PBR28 on
healthy controls and RRMS patients showed good repro-
ducibility of the ligand’s distribution volume (VT) esti-
mates in WM and GM as well as in focal MS lesions with a
test–retest variability of 7–9 % [64, 65]. Another test–ret-
est study with [11C]PBR28 on healthy controls [66] showed
higher mean absolute variability in VT in GM
(13.8–25.9 % depending on the region). However, the
intraclass reliability, measured with intraclass correlation
coefficient (ICC) was high, with ICC ranging from 0.90 to
0.94 in the GM regions, and with no significant differences
between the MAB and HAB subgroups. In accordance with
the results with [11C]PBR28, a study with [18F]PBR111
[67], where the subjects were matched according to their
TSPO binding genotype, showed that the TSPO binding
was increased in the T2 lesional and perilesional WM of
RRMS patients (n = 11) when compared to healthy con-
trols (n = 11), and the ratio of VT in the T2-lesional WM
versus NAWM appeared to correlate with the disease
severity (measured with the multiple sclerosis severity
scale, MSSS).
These results suggest that TSPO-PET could be used for
monitoring pharmacological effects targeting neuroin-
flammation. Moreover, with the stratification of study
subjects according to the TSPO binding phenotype now
being feasible with simple PCR testing [51], it is probable
that the second-generation TSPO ligands will be utilised
increasingly in MS studies.
TSPO-PET studies of progressive MS patients
The ability to detect activated microglial cells/macro-
phages related to focal inflammatory lesions using TSPO-
PET takes MS imaging a step forward from MRI imaging
in terms of specificity. MRI detects mostly changes in
464 Clin Transl Imaging (2015) 3:461–473
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water content in the pathological tissues, but with molec-
ular imaging can one detect specific cell types, depending
on the specificity of the radioligand in use. It is known
from neuropathology studies, that in SPMS and in PPMS
there is a diffuse, widespread inflammatory process within
the CNS with activation of microglial cells also outside
plaque areas, which is closely associated with axonal
damage [6]. This diffuse inflammation cannot be detected
using conventional MRI, but with careful modelling, it can
be quantified in vivo using TSPO-PET. The impact of
TSPO-PET imaging and the unique opportunity it gives by
allowing in vivo visualisation of the functional change of a
cell within the brain that has a major role in the pathology
of MS is only beginning to be appreciated. In PPMS,
TSPO-PET studies are still mostly lacking, but it has been
clearly demonstrated in in vivo studies that [11C]-PK11195
binding in the NAWM of SPMS is significantly increased
when compared to age-matched healthy controls [34, 48,
49, 57]. In these studies, all focal inflammatory lesions
have been carefully masked out, and the tissue of interest
comprises areas appearing normal in MRI. Hence, in this
application, TSPO-PET is providing truly complementary
Table 1 Summary of study design and study population characteristics in [11C]PK11195 PET MS studies

















































































































































0.4 (0.2) 1.7 (1.0) None 0 np
EDSS expanded disability status scale, RRMS relapsing–remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, PPMS
primary progressive multiple sclerosis, HC healthy control, PMS (progressive multiple sclerosis), CIS clinically isolated syndrome, np infor-
mation not provided, DMT disease-modifying treatment, IFN-b beta-interferon, GA glatiramer acetate (initiated after baseline imaging), CP
cyclophosphamide, GA glatiramer acetate
¤ One patient with a relapse 4 weeks prior to scan, resolving acute lesion in MRI at the time of PET scan
* Of all patients, disease subtype not specified
£ Median number (range) of gadolinium-enhancing lesions at baseline: 0 (0–15)
§ Median volumes of gadolinium-enhancing lesions: RRMS 144 mm3, SPMS 89 mm3
# 8 SPMS patients and 1 PPMS patient pooled into one group of PMS patients
& Longitudinal follow-up for clinical parameters
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information to MRI. Moreover, our preliminary work
demonstrates that microglial activation measured in the
NAWM of MS patients closely correlates to patients’ dis-
ability evaluated using Expanded Disability Status Scale
(EDSS) and age. Importantly, our results suggest a pres-
ence of a threshold in the level of TSPO radioligand
binding, which segregated the patients within our cohort to
RRMS and SPMS clinical subgroups (Rissanen et al.,
submitted). Giannetti et al. demonstrated that TSPO bind-
ing in T1 black holes of progressive patients may correlate
with clinical disability and was predictive of disease pro-
gression [47]. However, black holes with smaller volume
were shown to have higher TSPO binding compared to
larger lesions in RRMS patients and hence this observation
might to some extent be due to partial volume effect and
should be interpreted with caution.
The conversion of RRMS to SPMS is insidious and may
be difficult to determine clinically. At this stage, the
patients may experience increasing difficulties with bladder
control, spasticity, cognition and weakness. Measuring
EDSS has proven to have limited use for prediction of
SPMS [68], and the ability of conventional MRI parame-
ters to predict progression of disease is similarly limited
[69]. It would be, however, highly important to be able to
detect patients on the verge of SPMS to be able to prevent,
or efficiently treat SPMS. While increasing atrophy and
enlarging black holes can be detected in longitudinal fol-
low-up as MRI signs of progressive disease, the informa-
tion is inevitably retrospective, whereas treatment
decisions aiming to slow down progression need to be done
prospectively. Here, TSPO imaging may be of help, as PET
enables the detection of microglial activation in the
NAWM, an alteration which likely precedes development
of gross atrophy and might promptly respond to therapy
owing to the highly plastic nature of microglial cells [61].
Hence, it might be possible to use TSPO imaging as a
biomarker to help evaluate the MS disease stage and
severity, and even to predict the conversion of RRMS to
SPMS disease, prior measurable clinical signs of perma-
nent disability have emerged. TSPO imaging might thus
help to alleviate the clinico-radiological paradox in MS.
Longitudinal studies with clinical follow-up and imaging in
same patients are needed to evaluate this further.
TSPO imaging might also be valuable in distinguishing
features of focal pathology in SPMS. Neuropathology
studies have defined various types of plaques in MS. These
can be detected both in the WM and in the GM, and they
vary in composition depending on the disease stage [6].
The WM lesions in RRMS are typically of the active-lesion
type, and they are likely the pathologic correlate of clinical
attacks [5]. In SPMS, the plaques are mostly of the chronic
active, slowly expanding (smouldering), or chronic inac-
tive derivatives, with the classification depending on the
presence and distribution of macrophages and activated
microglial cells in the plaque edge [6]. In our in vivo PET
studies of SPMS patients, we demonstrated that TSPO
imaging can be used to differentiate the chronic active and
chronic inactive plaques also in vivo, a manifestation of
microglial cell activation not detectable by MR imaging
(Figs. 1, 2). In our cohort of advanced SPMS patients,
57 % of the plaques were of the chronic active type, with
increased TSPO binding at the plaque edge [49]. The
evaluation of TSPO binding could thus be used for in vivo
differentiation between different subtypes of chronic
lesions, and its usability as an outcome measure should be
tested in treatment studies of progressive disease.
Fig. 1 In vivo differentiation of
chronic T1 lesions using TSPO-
PET. Left image a T1-weighted
MRI image with two similar-
looking (non-gadolinium-
enhancing) T1 black holes.
TSPO-PET (on the right) shows
that in the upper lesion there is
microglial activation,
confirming this lesion to be a
chronic active lesion, whereas
in the lower lesion there is no
radioligand uptake, confirming
this lesion to be a chronic
inactive lesion
468 Clin Transl Imaging (2015) 3:461–473
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Considerations on methodological challenges
Until today, the methods for the modelling of dynamic
brain [11C](R)-PK11195 imaging have varied from study
to study due to the lack of harmonisation of protocols. For
instance, in some of the earlier studies using
[11C]PK11195, cortical gray matter has been used as a
reference region, whereas in others it was the main target
of interest [48, 57, 59]. The use of a clustered reference
region appears to now have established its position in the
estimation of specific ligand binding in clinical studies,
and there is hope for more homogenous methodology and
better comparison of results between different studies [47–
49, 61]. It appears likely that reference region clustering
could be developed also for second-generation TSPO
ligands in future studies. Nonetheless, subtle differences in
the results between study groups may arise from differ-
ences in image reconstruction protocols and PET scanner
features, as well as due to the different methods used for
kinetic modelling and ROI acquisition, and for calculating
the parametric images (Table 2). In the PET imaging
studies of progressive MS, the target of interest is acti-
vated microglial cell expressing TSPO (the cell type
believed to be related to neurodegeneration). As there is
also strong expression of TSPO on endothelial cells, and
as the brain is very heavily vascularised, it is a major
modelling challenge to omit the blood vessel-derived
TSPO signal when using TSPO ligands for evaluating
microglial activation. Cortical microglial signal especially
can be contaminated by the TSPO signal arising from the
large blood vessels close to the cortex. Importantly,
attempts have been made to overcome this problem with
novel kinetic modelling [70]. Development of improved
methods for co-registration of MRI and PET scans and
motion correction of PET scans will also help to exclude
unwanted signal, and to detect the specific signal of the
cell type of interest. Another potential source of biological
variance in TSPO studies of MS is activated astrocytes,
which also express TSPO at least at some circumstances
[35]. It would be a major advantage if in the future the
different study centres would work together to harmonise
and validate protocols for image acquisition, processing
and modelling for use in future studies of progressive MS.
Another important aspect of the methodological develop-
ment of MS PET studies is the notion that all novel PET
radioligands can presently be evaluated in preclinical
models of MS disease before application in (the very
expensive) human studies. This pathway has already been
used in case of MS and TSPO imaging [71].
Other targets for evaluation of neuroinflammation
in MS
Adenosine A2A receptors
Adenosine is a ubiquitous purine, which acts by binding to
four types of widely expressed G-protein-coupled recep-
tors, namely A1R, A2AR, A2BR, and A3R. Adenosine-
mediated signalling leads to modulation of inflammation
[72], and in the peripheral immune system, especially the
A2AR-mediated effects efficiently attenuate inflammation
[73]. A2ARs are strongly upregulated at sites of inflam-
mation and tissue damage, thus providing an endogenous
way to limit inflammation [74]. In the CNS, the outcome of
A2AR-mediated signalling is, however, much less clear
[75]. We have studied the NAWM of SPMS patients using
PET and a radioligand [11C]TMSX ([7-N-methyl-11C]-
(E)-8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine)
binding to A2A receptors, and found increased expression
of A2AR in the NAWM of patients compared to controls
[76]. Our work demonstrates the potential usefulness of
[11C]TMSX-PET imaging in clarifying the diffuse patho-
logic alterations in the NAWM associated with progressive
MS disease. The method could thus complement the TSPO
imaging approaches in progressive MS.
Fig. 2 PK11195 binding patterns in MS. A schematic drawing of
PK11195 binding patterns in T1 lesional (centre of the circle) and
perilesional (yellow rim of the circle) WM and NAWM in RRMS
compared to SPMS. Red dots PK11195 binding as a sign of microglial
activation. RRMS = relapsing–remitting multiple sclerosis;
SPMS = secondary progressive multiple sclerosis; Gd ? = gadolin-
ium positive; Gd- = gadolinium negative; NAWM = normal
appearing white matter
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Other targets
Several other promising targets that have not yet been
utilised in MS research have emerged in the field of
imaging neuroinflammation. Purinoreceptor P2X7 has been
linked to microglia-mediated neuroprotection via activa-
tion of the receptors by ATP [77]. Novel P2X7 antagonists
have been developed, and are promising candidates for
being used as P2X7 PET tracers [78, 79]. Cannabinoid
receptor 2 (CB2) is also expressed in activated microglia
[80], and consequently, numerous ligands have recently
been developed and pre-clinically tested [81–84]. In addi-
tion, histamine 4 (H4) and cyclo-oxygenase 2 (COX-2)
receptors being involved also in neuroinflammation, and
folate receptors being linked to many inflammatory and
autoimmune diseases, appear as interesting future targets
for PET imaging of neuroinflammation [85–87].
Conclusions
TSPO-PET imaging has potential for evaluation of MS
pathology in vivo in a sensitive and quantifiable way at
molecular level, and thus gives added value over conven-
tional MRI. This would be especially useful for evaluation
of progressive MS, where TSPO-PET allows detection of
diffuse pathology in the NAWM. TSPO-PET could thus
potentially be used as an imaging biomarker of diffuse
neuroinflammation related to disease progression in MS
and could help to identify patients who will soon enter the
progressive phase of the disease. This is especially
important when striving to develop disease-modifying
therapies in progressive MS, where conventional imaging
markers are known to correlate inadequately with the
clinical phenotype and the prognosis of the disease, and
where there is presently a great unmet need [88–90]. Here,
TSPO imaging might prove valuable as a surrogate marker.
There are, however, still technical challenges, and it is our
task in the future to try to harmonise and validate the
methodology to be able to perform multi-centre studies
using TSPO-PET. This would help to improve the design
of future clinical trials and to allow the measurement of the
effects of new drugs aimed at reducing neurodegeneration
and neuroinflammation contained within the CNS. Further
work is needed to understand the TSPO signal in terms of
microglial activation phenotype, and to develop new
ligands potentially better at distinguishing between differ-
ent phenotypes.
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